MIRM Logo

Mirum Pharmaceuticals, Inc. (MIRM) 

NASDAQ$44.56
Market Cap
$2.18B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
192 of 925
Rank in Industry
116 of 528

MIRM Insider Trading Activity

MIRM Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$370,9671037
Sells
$5,860,1581763

Related Transactions

Heron Patrick Jdirector8$269,7670$0$269,767
BJERKHOLT ERICCHIEF FINANCIAL OFFICER2$101,2000$0$101,200
Ramasastry Sairadirector0$01$128,400$-128,400
Howe JolandaSVP, GLOBAL CONTROLLER0$05$257,150$-257,150
Quan JoanneCHIEF MEDICAL OFFICER0$01$319,598$-319,598
Vig PamelaCHIEF SCIENTIFIC OFFICER0$01$1.04M$-1.04M
Radovich PeterPRESIDENT AND COO0$05$1.15M$-1.15M
Peetz ChristopherCHIEF EXECUTIVE OFFICER0$04$2.96M$-2.96M

About Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, â€¦

Insider Activity of Mirum Pharmaceuticals, Inc.

Over the last 12 months, insiders at Mirum Pharmaceuticals, Inc. have bought $370,967 and sold $5.86M worth of Mirum Pharmaceuticals, Inc. stock.

On average, over the past 5 years, insiders at Mirum Pharmaceuticals, Inc. have bought $1.37M and sold $5.03M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Heron Patrick J (director) — $269,767. BJERKHOLT ERIC (CHIEF FINANCIAL OFFICER) — $101,200.

The last purchase of 963 shares for transaction amount of $42,155 was made by Heron Patrick J (director) on 2025‑03‑11.

List of Insider Buy and Sell Transactions, Mirum Pharmaceuticals, Inc.

2025-03-11PurchaseHeron Patrick Jdirector
963
0.002%
$43.77$42,155+1.76%
2025-03-10PurchaseHeron Patrick Jdirector
1,335
0.0027%
$42.97$57,363+3.60%
2025-03-07PurchaseHeron Patrick Jdirector
580
0.0012%
$43.21$25,064+1.96%
2025-03-06PurchaseHeron Patrick Jdirector
1,335
0.0027%
$43.89$58,597+1.29%
2025-03-05PurchaseHeron Patrick Jdirector
267
0.0005%
$44.55$11,894-1.93%
2025-03-04SaleRadovich PeterPRESIDENT AND COO
14,850
0.0305%
$45.58$676,928-2.65%
2025-03-04PurchaseHeron Patrick Jdirector
1,335
0.0027%
$45.57$60,830-2.65%
2025-03-03SalePeetz ChristopherCHIEF EXECUTIVE OFFICER
40,000
0.0836%
$46.91$1.88M-3.70%
2025-02-03SalePeetz ChristopherCHIEF EXECUTIVE OFFICER
9,102
0.0187%
$48.22$438,921+3.23%
2025-02-03SaleRadovich PeterPRESIDENT AND COO
2,627
0.0054%
$48.22$126,681+3.23%
2025-02-03SaleHowe JolandaSVP, GLOBAL CONTROLLER
1,064
0.0022%
$48.22$51,309+3.23%
2025-01-24SalePeetz ChristopherCHIEF EXECUTIVE OFFICER
6,837
0.0143%
$47.92$327,658+2.84%
2025-01-24SaleRadovich PeterPRESIDENT AND COO
3,177
0.0066%
$47.92$152,256+2.84%
2025-01-24SaleHowe JolandaSVP, GLOBAL CONTROLLER
902
0.0019%
$47.92$43,228+2.84%
2025-01-17SaleQuan JoanneCHIEF MEDICAL OFFICER
6,969
0.0143%
$45.86$319,598+3.51%
2025-01-07SalePeetz ChristopherCHIEF EXECUTIVE OFFICER
7,489
0.0159%
$42.82$320,644+15.22%
2025-01-07SaleRadovich PeterPRESIDENT AND COO
1,998
0.0043%
$42.82$85,545+15.22%
2025-01-07SaleHowe JolandaSVP, GLOBAL CONTROLLER
750
0.0016%
$42.82$32,111+15.22%
2024-11-14SaleHowe JolandaSVP, GLOBAL CONTROLLER
2,500
0.0053%
$47.10$117,752-2.66%
2024-09-18PurchaseHeron Patrick Jdirector
115
0.0002%
$37.40$4,301+13.59%
Total: 105
*Gray background shows transactions not older than one year

Insider Historical Profitability

26.78%
Heron Patrick Jdirector
168123
0.343%
$7.49M130+0.01%
Peetz ChristopherCHIEF EXECUTIVE OFFICER
115920
0.2365%
$5.17M49+41.16%
Vig PamelaCHIEF SCIENTIFIC OFFICER
27406
0.0559%
$1.22M16+53.04%
BJERKHOLT ERICCHIEF FINANCIAL OFFICER
14000
0.0286%
$623,840.0030<0.0001%
BARRIS PETER J10 percent owner
4186243
8.5409%
$186.54M10+5.09%
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$66,492,695
135
27.65%
$2.03B
$1,376,668
53
18.46%
$2.27B
Mirum Pharmaceuticals, Inc.
(MIRM)
$224,267,561
40
26.78%
$2.18B
$62,927,079
29
14.02%
$2.25B
$150,253,463
26
-52.83%
$2.22B

MIRM Institutional Investors: Active Positions

Increased Positions115+65.34%4M+6.79%
Decreased Positions74-42.05%3M-6.47%
New Positions41New1MNew
Sold Out Positions14Sold Out637,134Sold Out
Total Postitions217+23.3%53M+0.31%

MIRM Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Frazier Life Sciences Management, L.P.$312,554.0013.41%6.57M00%2024-12-31
Janus Henderson Group Plc$217,949.009.35%4.58M+101,358+2.26%2024-12-31
Blackrock, Inc.$163,385.007.01%3.43M+66,471+1.97%2024-12-31
Bvf Inc/Il$133,030.005.71%2.8M-279,394-9.08%2024-12-31
Eventide Asset Management, Llc$124,012.005.32%2.61M-838,425-24.34%2024-12-31
Vanguard Group Inc$115,345.004.95%2.42M-71,378-2.86%2024-12-31
Citadel Advisors Llc$71,887.003.08%1.51M+119,774+8.61%2024-12-31
Novo Holdings A/S$71,355.003.06%1.5M00%2024-12-31
Rock Springs Capital Management Lp$70,002.003%1.47M-108,924-6.89%2024-12-31
Price T Rowe Associates Inc /Md/$67,679.002.9%1.42M+138,623+10.79%2024-12-31

Financial Ratios

Summary
Comparison with Competitors

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
1.6SellsBuysStrong BuyBuyHoldSellStrong SellMIRMHighAverageLowSeries 4